Hepatic hazard assessment of silver nanoparticle exposure in healthy and chronically alcohol fed mice

Tidsskriftartikel - 2017


Silver (Ag) nanoparticles (NPs) are currently among one of the most widely used nanomaterials. This in turn, implies an increased risk of human and environmental exposure. Alcohol abuse is a global issue with millions of people in the general population affected by the associated adverse effects. The excessive consumption of alcohol is a prominent cause of chronic liver disease which manifest in multiple disorders. In this study the adverse health effects of Ag NP exposure were investigated in models of alcoholic hepatic disease in vitro and in vivo. The data showed that Ag NP induced hepatic health effects were aggravated in the alcohol pre-treated mice in comparison to controls with regards to an organ specific inflammatory response, changes in blood biochemistry, acute phase response and hepatic pathology. In addition, alcoholic disease influenced the organ's ability for recovery post NP challenge. Additionally, it is demonstrated that the in vivo data correlated well with in vitro findings where ethanol pre-treatment of hepatocytes resulted in significantly increased inflammatory response post Ag NP exposure. To the best of our knowledge this is the first study of its kind to investigate nano-sized material-induced hepatic pathology in models representative of susceptible individuals (those with pre-existing alcohol liver disease) within the population. This is an area of research in the field of nanotoxicology, and in particular with regards to NP risk assessment that is almost entirely overlooked.


Kermanizadeh A, Jacobsen NR, Roursgaard M, Loft S, Møller P. Hepatic hazard assessment of silver nanoparticle exposure in healthy and chronically alcohol fed mice. Toxicological Sciences 2017;158(1):176-187.
doi: 10.1093/toxsci/kfx080

Gå til Tidsskriftartikel

Relaterede projekter

Dansk Center for Nanosikkerhed

NFA logo

Det Nationale Forskningscenter for Arbejdsmiljø | Lersø Parkallé 105 | 2100 København Ø. | T: 39 16 52 00 | F: 39 16 52 01 | M: nfa@nfa.dk | CVR: 15 41 37 00